08/23/2012
Reported online last week in Science Translational Medicine, researchers at MIT and Harvard used nanoparticles to demonstrate the nanoparticles that target a protein called ID4 can reduce ovarian cancer tumors in mice.
Researchers hope that this approach could help speed the development of new drugs. As new technology allows researchers to sequence cancer cell genomes, researchers are finding more and more gene mutations and deletions that may be therapeutic targets. This approach—using a mouse model to determine which ones are important—may help researchers prioritize which ones to focus drug development efforts on.
Click here for the abstract.
Related Topics

OCRA Sponsors NCCN 2025 Guidelines for Cervical Cancer Patients
This article was updated in May 2025 to reflect NCCN’s release of the 2025 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of 2025 Cervical Cancer Updates. We … Continued

FDA Gives Its First-Ever Approval of Treatment for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with … Continued

OCRA’s Early Career Investigator Grant Recipients
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These … Continued